Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05918861

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS (dal-GenE-2)

Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)

Sponsor: DalCor Pharmaceuticals

Conditions Acute Coronary Syndrome

Interventions Dalcetrapib Placebo

Updated 19 times since 2023 Last updated: Jan 5, 2026 Started: Oct 3, 2023 Primary completion: Aug 31, 2027 Completion: Aug 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05918861, this PHASE3 trial focuses on Acute Coronary Syndrome and remains actively recruiting participants. Sponsored by DalCor Pharmaceuticals, it has been updated 19 times since 2023, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

19 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3
Sep 2025 — Feb 2026 [monthly]

Recruiting PHASE3
May 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Apr 2025 — May 2025 [monthly]

Recruiting PHASE3
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE3

▶ Show 14 earlier versions

Jan 2025 — Mar 2025 [monthly]

Recruiting PHASE3
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Mar 2024 — May 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Mar 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Oct 2023 — Nov 2023 [monthly]

Not Yet Recruiting PHASE3
Jul 2023 — Oct 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

DalCor Pharmaceuticals
The Montreal Health Innovations Coordinating Center (MHICC)

Data source: DalCor Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abbotsford, Canada , Acworth, United States , Albany, United States , Albuquerque, United States , Alexander City, United States , Allentown, United States , Amarillo, United States , Arlington Heights, United States , Atlanta, United States , Augusta, United States and 180 more locations